Inato, founded in 2016 and headquartered in Paris, France, is a company developing an artificial intelligence module that matches biopharmaceutical trials to qualified testing sites around the world. Inato works in conjunction with pharmaceutical companies and Contract Research Organizations to develop a marketplace for clinical research sites around the world.

Inato has a second office located in New York. Their services have been utilized in over 75 countries, accounting for over 3,500 doctors and 2,000 testing sites. Inato's AI system utilizes the following data points:
- Patient accessibility
- Location capacity
- Doctor participation interest
- In-network sites willing to assist in patient accessibility
Inato's Anticovid Platform gathers, organizes, and analyzes all COVID-19 clinical trial data in one open-access hub. Anticovid presents these insights to hospitals and doctors at no charge to facilitate:
- Search and access for the most up-to-date COVID-19 trial information
- Analysis and understanding of the emerging COVID-19 clinical trial trends, so that medical professionals can participate in or support in trials.
Timeline
Patents
Further Resources
Another Venture Attempts to Conquer Research Site Selection with Algorithmic-based Performance Metrics
Web
February 5, 2020
Inato raises $14M to unlock trial site potential
Ben Adams
Web
February 5, 2020
Inato Unveils Central, Searchable Repository for all COVID-19 Clinical Trials
Inato SAS
Web
April 14, 2020
Paris-based Inato raises €1.3 million to lower drug prices through better clinical trial recruitment
Thomas Ohr
Web
November 15, 2017
Serena, Obvious Ventures Invest In This Clinical Trial Marketplace's $14M Series...
Natasha Mascarenhas
Web
February 4, 2020